142 related articles for article (PubMed ID: 20213647)
21. Structural insights into the function of type IB topoisomerases.
Redinbo MR; Champoux JJ; Hol WG
Curr Opin Struct Biol; 1999 Feb; 9(1):29-36. PubMed ID: 10047584
[TBL] [Abstract][Full Text] [Related]
22. Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition.
Perego P; Cossa G; Tinelli S; Corna E; Carenini N; Gatti L; De Cesare M; Ciusani E; Zunino F; Luison E; Canevari S; Zaffaroni N; Beretta GL
Biochem Pharmacol; 2012 Jan; 83(1):27-36. PubMed ID: 21978643
[TBL] [Abstract][Full Text] [Related]
23. Structure and properties of camptothecin derivatives, their protonated forms, and model interaction with the topoisomerase I-DNA complex.
Ivanova B; Spiteller M
Biopolymers; 2012 Feb; 97(2):134-44. PubMed ID: 21898362
[TBL] [Abstract][Full Text] [Related]
24. Camptothecin resistance related to drug-induced down-regulation of topoisomerase I and to steps occurring after the formation of protein-linked DNA breaks.
Murren JR; Beidler DR; Cheng YC
Ann N Y Acad Sci; 1996 Dec; 803():74-92. PubMed ID: 8993502
[No Abstract] [Full Text] [Related]
25. Iridoids as DNA topoisomerase I poisons.
Gálvez M; Martín-Cordero C; Ayuso MJ
J Enzyme Inhib Med Chem; 2005 Aug; 20(4):389-92. PubMed ID: 16206835
[TBL] [Abstract][Full Text] [Related]
26. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
Goldwasser F; Bae I; Fornace AJ; Pommier Y
Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
[TBL] [Abstract][Full Text] [Related]
27. The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor.
Demarquay D; Coulomb H; Huchet M; Lesueur-Ginot L; Camara J; Lavergne O; Bigg D
Ann N Y Acad Sci; 2000; 922():301-2. PubMed ID: 11193906
[No Abstract] [Full Text] [Related]
28. An ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNA-topoisomerase I ternary cleavage complexes.
Xiao X; Cushman M
J Am Chem Soc; 2005 Jul; 127(28):9960-1. PubMed ID: 16011334
[TBL] [Abstract][Full Text] [Related]
29. A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin.
Kerrigan JE; Pilch DS
Biochemistry; 2001 Aug; 40(33):9792-8. PubMed ID: 11502172
[TBL] [Abstract][Full Text] [Related]
30. Methyleugenol and oxidative metabolites induce DNA damage and interact with human topoisomerases.
Groh IA; Rudakovski O; Gründken M; Schroeter A; Marko D; Esselen M
Arch Toxicol; 2016 Nov; 90(11):2809-2823. PubMed ID: 26542539
[TBL] [Abstract][Full Text] [Related]
31. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff.
Strumberg D; Pilon AA; Smith M; Hickey R; Malkas L; Pommier Y
Mol Cell Biol; 2000 Jun; 20(11):3977-87. PubMed ID: 10805740
[TBL] [Abstract][Full Text] [Related]
32. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
Jung LL; Zamboni WC
Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
[TBL] [Abstract][Full Text] [Related]
33. Camptothecins as probes of the microenvironments of topoisomerase I--DNA complexes.
Hecht SM
Ann N Y Acad Sci; 2000; 922():76-91. PubMed ID: 11193927
[TBL] [Abstract][Full Text] [Related]
34. The effect of camptothecin on topoisomerase I catalysis.
Christiansen K; Westergaard O
Ann N Y Acad Sci; 1996 Dec; 803():50-9. PubMed ID: 8993500
[TBL] [Abstract][Full Text] [Related]
35. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Burris HA; Fields SM
Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
[TBL] [Abstract][Full Text] [Related]
36. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.
Gomez-Manzano C; Alonso MM; Yung WK; McCormick F; Curiel DT; Lang FF; Jiang H; Bekele BN; Zhou X; Alemany R; Fueyo J
Clin Cancer Res; 2006 Jan; 12(2):556-62. PubMed ID: 16428500
[TBL] [Abstract][Full Text] [Related]
37. [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target].
Tsunoda T
Nihon Rinsho; 2003 Sep; 61 Suppl 7():472-5. PubMed ID: 14574938
[No Abstract] [Full Text] [Related]
38. Topoisomerase I poisons and suppressors as anticancer drugs.
Bailly C
Curr Med Chem; 2000 Jan; 7(1):39-58. PubMed ID: 10637356
[TBL] [Abstract][Full Text] [Related]
39. Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study.
Pavillard V; Charasson V; Laroche-Clary A; Soubeyran I; Robert J
Anticancer Res; 2004; 24(2B):579-85. PubMed ID: 15160997
[TBL] [Abstract][Full Text] [Related]
40. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
